Inflammatory bowel disease: Epidemiology, pathology and risk factors for hypercoagulability

doi:10.3748/wjg.v20.i1.53

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7567)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

617

WORD

255

HTML

4334

Figures (1-4)

132

Tables (1-2)

115

Sum=5453

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1081

Download

1033

Sum=2114

Jan 7, 2014 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (66)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jan 7, 2014; 20(1): 53-63
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.53

Full Size Figure Download Figure

Figure 3 Plasma coagulation inhibitors. AT III: Antithrombin III; TF: Tissue factor; TFPI: TF pathway inhibitor; PS: Protein S; APC: Activated protein C. ↓: Changes in plasma coagulation inhibitors, in patients with inflammatory bowel diseases.

Citation: Owczarek D, Cibor D, Głowacki MK, Rodacki T, Mach T. Inflammatory bowel disease: Epidemiology, pathology and risk factors for hypercoagulability. World J Gastroenterol 2014; 20(1): 53-63
URL: https://www.wjgnet.com/1007-9327/full/v20/i1/53.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i1.53